Table of Contents
Executive Summary — 5
SWOT
Analysis — 6
France Pharmaceuticals And Healthcare
Industry SWOT — 6
France Political
SWOT — 7
France Economic SWOT — 7
Pharmaceutical Business Environment Ratings — 8
Table:
Western Europe Pharmaceutical Business Environment Rankings for
Q409 — 8
Risks to Realisation of
Returns — 9
France – Market
Summary — 10
Regulatory Regime — 11
Intellectual Property Developments — 11
Counterfeit
Drugs — 13
Pricing and Reimbursement
Issues — 13
France Reimbursement
Categories — 14
Recent Pricing and Reimbursement
Developments — 15
OTC Market
Developments — 17
Industry Trends And
Developments — 18
Epidemiology — 18
Table: Disease Burden In Western Europe — 19
Public Health
Issues — 19
Prescribing Habits — 21
Healthcare Financing — 22
Industry Forecast
Scenario — 24
Overall Market
Forecast — 24
France – Drug Market Expenditure,
2003-2013 — 25
Key Growth Factors –
Industry — 26
Table: France - Health Expenditure
Indicators, Historical Data and Forecasts — 27
Key Growth
Factors – Macroeconomic — 28
Table: France -
Economic Activity — 29
Prescription Market
Forecast — 30
Table: France - Prescription Drugs Market
Indicators, Historical Data and Forecasts (EURmn unless otherwise
stated) — 31
Patented Market
Forecast — 33
Table: France - Patented Drugs Market
Forecast Indicators, Historical Data and Forecasts — 34
Generics Market Forecasts — 35
Table: France - Generics
Market Indicators, Historical Data and Forecasts — 36
OTC
Market Forecast — 37
Table: France - OTC Drugs Market
Indicators, Historical Data and Forecasts (EURmn unless otherwise
stated) — 38
Pharmaceutical Trade
Forecasts — 39
Table: France – Trade Indicators,
Historical Data and Forecasts (US$mn) — 39
Other
Healthcare Data and Forecasts — 40
Table: France - Other
Healthcare Indicators, Historical Data and Forecasts — 40
Key Risks to BMI’s Forecasts — 40
Competitive
Landscape — 41
Pharmaceutical
Industry — 41
Recent Company
Developments — 42
Multinational
Companies — 44
Research and Development
Sector — 45
Biotechnology Sector — 46
Wholesale Sector — 47
Pharmacy
Sector — 48
Medical Devices — 49
Company Monitor — 50
Leading Multinational
Manufacturers — 50
Pfizer — 50
GlaxoSmithKline (GSK) — 52
Novartis — 54
Merck & Co — 56
Major
Indigenous Companies — 58
Sanofi-Aventis — 58
Servier — 61
Ipsen — 64
Country Snapshot: France Demographic
Data — 66
Section 1: Population — 66
Table: Demographic Indicators, 2005-2030 — 66
Table:
Rural/Urban Breakdown, 2005-2030 — 67
Section 2: Education
and Healthcare — 67
Table: Education,
2002-2005 — 67
Table: Vital Statistics,
2005-2030 — 67
Section 3: Labour Market and Spending
Power — 68
Table: Employment Indicators,
2000-2005 — 68
Table: Consumer Expenditure, 2000-2012
(US$) — 69
Table: Average Annual Wages,
2000-2012 — 69
BMI Forecast
Modelling — 70
How We Generate Our Pharmaceutical Industry
Forecasts — 70
Pharmaceutical Business Environment Ratings
Methodology — 71
Ratings Overview — 71
Table: Pharmaceutical Business Environment Indicators — 72
Weighting — 73
Table: Weighting Of
Components — 73
Sources — 73
| 
View Cart
